Phase 3 N=991 A Study of SI-6603 in Patients With Lumbar Disc Herniation
Intervertebral Disc Disease · Lumbar Disc Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 615 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=643 Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
HIV Infections
Primary: Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery — 97.5; 91.0; 97.5; 91.4 Percentage of participants — p=0.005
Phase 3 N=160 Metoclopramide for Post Traumatic Headache
Post-Traumatic Headache
Primary: 0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable — 5.2; 3.8 units on a scale
Phase 3 N=363 Autologous Transplant for Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants Achieving a Complete Response — 51 Participants
Phase 3 N=132 Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
Urinary Retention · Lower Urinary Tract Symptoms · Stress Urinary Incontinence
Primary: Postoperative Urinary Retention — 16; 5 Participants
Phase 3 N=165 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Influenza (Healthy Volunteers)
Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 0 — 23.6; 24.1; 111; 169 titers
Phase 3 N=160 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms
Bone Metastases
Primary: Number of Intent- to- Treat Patients With Pain Response by Treatment — 19; 34; 24; 36 Participants — p=.03
Phase 3 N=188 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
MRSA · Cystic Fibrosis
Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted — 2.39; 1.18; 1.52; 0.13 Percent predicted — p=0.325
Phase 3 N=501 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) in the Global Population — 13.24; NA; 13.40; 19.22 months — p=0.0006
Phase 3 N=134 Rizatriptan for Episodic Dizziness in Vestibular Migraine
Vestibular Migraine · Migrainous Vertigo
Primary: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild — 50; 73 Episodes — p=<0.33
Phase 3 N=499 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Primary: Overall Survival (OS) — 10.9; 10.4 months — p=0.1779
Phase 3 N=614 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Anaemia
Primary: Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28) — 0.19; 1.58 Grams per deciliter — p=<0.0001
Phase 3 N=1,106 Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Primary: Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period — 0.54; 0.67 Confirmed relapses — p=0.0024
Phase 3 N=243 AR101 Real-World Open-Label Extension Study
Peanut Allergy
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) — 219; 176; 43; 0 Participants
Phase 3 N=506 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Peanut Allergy
Primary: Frequency of Treatment Emergent Adverse Events, Including Serious Adverse Events — 334; 159; 171; 110 Participants